Handelsavisen
prelaunch
Companies ›Healthcare ›301602.SZ
30
301602.SZ — Shenzhen Stock Exchange Advanced Medical Equipment & Technology

Shantou Institute of Ultrasonic Instrument Co Ltd

¥17,20
Open in Charts → Attach watcher ⌖
— —
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,56 %
Op margin
42,1 %
ROE
10,9 %
Net margin
36,7 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Shantou Institute of Ultrasonic Instrument Co Ltd designs, develops, and produces ultrasonic medical equipment, primarily used in diagnostic imaging and therapeutic applications.

Business. Shantou Institute of Ultrasonic Instrument Co Ltd (301602.SZ) is a healthcare equipment manufacturer specializing in advanced medical equipment and technology. The company is headquartered in Shantou and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
ActivityHealthcare Equipment
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
10,9 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 301602.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 301602.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Shantou Institute of Ultrasonic Instrument Co Ltd (301602.SZ) is a healthcare equipment manufacturer specializing in advanced medical equipment and technology. The company is headquartered in Shantou and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    ActivityHealthcare Equipment
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a current ratio of 11.62, indicating a high ability to meet short-term obligations. Free cash flow stands at 101.38 million CNY, and operating cash flow is 135.25 million CNY, suggesting robust cash generation from operations. The debt-to-equity ratio is 0.0, reflecting a conservative capital structure with no long-term debt.

    Profitability metrics show a return on equity of 10.94% and a return on assets of 10.01%, both exceeding the typical thresholds for the healthcare equipment industry. Gross profit of 287.99 million CNY and operating income of 170.57 million CNY indicate strong cost control and operational efficiency.

    The company operates as a single business segment, with all revenue derived from the sale of ultrasonic medical equipment. There is no geographic diversification disclosed, and the company is entirely focused on the domestic Chinese market.

    Outlook data is not available for the next fiscal year, but historical revenue growth is evident, with a total revenue of 405.51 million CNY in the latest reporting period. The company has not disclosed specific growth targets or projections for the upcoming year.

    Risk factors include a medium liquidity risk, primarily due to the company's reliance on cash flow from operations to fund its activities. Although dilution risk is currently low, the absence of long-term debt does not preclude future financing needs that could lead to share dilution. No recent events or filings have been disclosed that would significantly impact the company's operations or financial position.

    Key takeaways
    • The company has a strong liquidity position with a high current ratio and positive free cash flow.
    • Profitability metrics are robust, with return on equity and return on assets exceeding industry norms.
    • The company operates as a single segment with no geographic diversification, which may increase exposure to local market risks.
    • There is no long-term debt, indicating a conservative capital structure and low financial leverage.
    • The company's growth trajectory is supported by strong cash flow generation, but future projections are not disclosed.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥17,20
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    ¥1.36B
    Net cashⓘ
    -¥1.7M
    Current ratioⓘ
    11.6
    Debt / equityⓘ
    0.0
    ROAⓘ
    10.0%
    ROEⓘ
    10.9%
    Cash conversionⓘ
    91.0%
    CapEx / revenueⓘ
    -3.8%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin42,1 %Above P75
    Net Margin36,7 %Above P75
    ROE10,9 %Above P75
    Capex / Rev-3,8 %Below median
    D/E0,00Above median
    Cash Conv0,91Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Shantou Institute of Ultrasonic Instrument Co Ltd Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    301602.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage